Spondyloarthritis
Adela Castro AdelaCastro222
4 months 2 weeks ago
‼️Diagnosis of axSpA is clinical
-MRI is a tool but still has a lot of limitations.
-Improve reports by directly communicating with radiology and be specific on pt clinical info.
-Unified algorithms are needed to apply AI in dx of SIJ inflammation on MRI.
#EULAR2025 @RheumNow https://t.co/9GR6FsgIcL
Adela Castro AdelaCastro222
4 months 2 weeks ago
🔍MRI lesions in early axSpA vs non axSpA with chronic back pain:
-Data from SPACE cohort
-n 318 (214 axSpA vs 108 non-axSpA).
-Baseline imaging (CR and MRI) and at 2y f/u
-Minimal progression on CR in both early axSpA and non-axSpA CBP.
-On MRI, significant increase in the https://t.co/m5YOAiFUz1
Dr. John Cush RheumNow
4 months 2 weeks ago
Difficult-to-Manage AxSpA: Global Prevalence and Associated Factors
The concept of D2M axSpA is a recent development, with the first expert consensus definition published by the Assessment of SpondyloArthritis International Society (ASAS) earlier this year. https://t.co/KmfJvAtwp0
Nelly ZIADE 🍀 Nellziade
4 months 2 weeks ago
Among 200 #axSpA pts from Rheumazentrum Ruhrgebiet
🔴Performance tests (SPPB)
were associated with
🔴Global functioning and health (ASAS-HI and other PROs)
What does this mean?
Improving physical performance could enhance PROs & QOL
#EULAR2025
POS#
@RheumNow
@XBaraliakos https://t.co/P3Q5NDvtoj
Nelly ZIADE 🍀 Nellziade
4 months 2 weeks ago
#D2M_axSpA_saga 🇬🇷
Prevalence of D2M axSpA in 395 patients: 10.1%
Associated factors:
🔹️High disease activity at diagnosis
🔹️Comorbidities (high BMI, smoking, depression)
🔹️Unemployment
Kougkas et al.
POS#0121
#EULAR2025
@rheumnow https://t.co/vcPcTATTx5
Adela Castro AdelaCastro222
4 months 2 weeks ago
🚨Diagnostic delays are real in axSpA:
-Can lead to more extra-msk manfieststions (EMMs) in PsA and axSpA.
-Increases disease burden and productivity losses.
-EMMs can present before articular sx
-Uveitis and IBD associated with longer dx delays.
-Diagnosis has improved since https://t.co/rWMwG7Ewwe
Jiha Lee JihaRheum
4 months 2 weeks ago
📊 SIJ findings in PsA (n=581):
🧠 31% = MRI-confirmed axSpA
🦴 Only 29% met r-mNY criteria
MRI-axPsA group: younger, more male, HLA-B27+
Clinical + radiographic definitely underperform vs MRI
#POS0297 @RheumNow #EULAR2025
Adela Castro AdelaCastro222
4 months 2 weeks ago
High dose NSAIDs and incidence of HTN in axSpA?
In pts with early axSpA(age at baseline 33.2 years) data from DESIR cohort showed that after adjusting for confounders,high dose NSAID use was not associated with incident hypertension (HR 1.01, 95% CI 0.98-1.02).
Interesting to
Adela Castro AdelaCastro222
4 months 2 weeks ago
What is new in SpA?
‼️nomenclature change:
🚫AS≠ Ankylosing spondylitis
✅AS= Axial spondyloarthritis
-Helena Marzo-Ortega at #EULAR2025
@RheumNow
Jiha Lee JihaRheum
4 months 2 weeks ago
Delay hurts.
Dx delay in axial SpA costs UK £3.1 billion annually.
Avg time to dx = 8.5 yrs
Avg dx cost = £187k/person
Fixing delay could save £167k/person.
Early Dx isn’t just better care—it’s economic policy.
#EULAR2025 @RheumNow
#AxialSpA #RMD https://t.co/eYEQ2rp94m
IL-17 inhibitors are an effective therapeutic for a broad spectrum of inflammatory and autoimmune diseases and its blockade has revolutionized management of diseases such as psoriasis, psoriatic arthritis and SpA. Is there a need for more medications within the same therapeutic class?
New work presented at the 2025 annual EULAR congress in Barcelona focuses on the recombinant zoster vaccine (RZV), which contains recombinant glycoprotein E – the major target of CD4+T-cells. The abstract describes the tolerability and safety of RZV in patients with inflammatory rheumatic and musculoskeletal diseases (iRMD), showcasing interim data from an ongoing study.
Nelly ZIADE 🍀 Nellziade
4 months 2 weeks ago
Diagnostic delay in #SpA
🔹️Data from the @Official_ASAS
Study
🔹️4339 patients
🔹️Delay was 6.6 years
🔹️Longer in axSpA and IBD-SpA, shorter in PsA and pSpA
🔹️Associated with type of initial symptoms (shorter in peripheral)
POS0909 #EULAR2025
@rheumnow https://t.co/3BMYFxbKiq
Adela Castro AdelaCastro222
4 months 2 weeks ago
LDCT to assess disease progression in early axSpA:
-Data from SPACE cohort 67 pts (>50% male,>80% hLAB27+)
- LDCT at baseline and 2 years apart.
-Overall 22% pt with net disease progression.
-Spine progression most frequent on thoracic spine.
-Good reliability in assessing https://t.co/M2jkDusD41
The longest studied drug for uveitis in SpA has been monocolonal TNFi Abs. Reductions of acute anterior uveitis have been found with etanercept but less impressively than adalimumab, infliximab, and in my opinion less than golimumab and certolizumab pegol.
Other data have emerged for JAKi and IL17i, with respect to acute anterior uveitis.
Poster Hall